Simultaneous Plethysmography and Electromyography Recording in an ALS Mouse Model

Executive Industry Relevance

This method enables simultaneous monitoring of respiratory muscle activity and ventilation in ALS mouse models, supporting mechanistic de-risking of therapeutic hypotheses related to neuromuscular decline. By quantifying EMG and plethysmography signals in freely moving animals, it provides predictive confidence in target validation for respiratory function modifiers. The approach aids preclinical model refinement and translational biomarker alignment for neurodegenerative disease programs.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses by correlating scalene and trapezius muscle EMG activity with ventilatory patterns in ALS models.
• Operational Value: Enables biological de-risking through repeated, longitudinal measurement of accessory muscle contribution to breathing.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems for downstream compound evaluation by establishing baseline respiratory-muscle coordination.
• Operational Value: Supports assay standardization via synchronized plethysmography and wireless EMG outputs under resting and moving conditions.

Translational & Preclinical Research

• Scientific Value: Aligns with disease-relevant system requirements by modeling respiratory complications in ALS through dual-signal acquisition.
• Operational Value: Ensures translational continuity from discovery to preclinical validation by capturing functional readouts relevant to clinical respiratory endpoints.

Pipeline & Workflow Integration

The method integrates into the discovery continuum from target validation through preclinical research, enabling hypothesis testing of neuromuscular modifiers and supporting go/no-go decisions based on respiratory muscle function.

• Discovery Biology: Supports mechanistic de-risking by clarifying pathway-specific contributions of accessory muscles to ventilation in ALS.
• Screening: Delivers assay readiness through reproducible, quantitative EMG and plethysmography signals that reflect real-time muscle activity during breathing.
• Analytics: Provides synchronized physiological readouts enabling comparative analysis of muscle activation patterns across experimental conditions.
• Translational Research: Connects to preclinical continuity by monitoring respiratory function as a translational biomarker aligned with clinical ALS progression.
• Enterprise Reuse: Functions as a reusable capability for longitudinal studies across multiple neurodegenerative models requiring respiratory phenotyping.

Operational & Enterprise Impact

• Scientific Value: Enhances predictive confidence by reducing mechanistic ambiguity in respiratory dysfunction pathways.
• Operational Value: Ensures standardization and reproducibility through implanted transmitter systems and chamber-based plethysmography.
• Strategic Value: Improves go/no-go decisions by providing early, quantitative insight into treatment effects on neuromuscular respiratory control.
• Portfolio Impact: Informs risk-adjusted prioritization of targets based on functional rescue of breathing-related muscle activity.

Implementation Considerations

• Requires expertise in surgical electrode implantation and wireless telemetry systems.
• Dependent on plethysmography chamber infrastructure and compatible receiver-transmitter pairs.
• Necessitates cross-team standardization between physiology, pharmacology, and data analysis groups.
• Involves adaptation considerations for different mouse strains and disease models beyond ALS.
• Limited by signal noise during high movement and the need for acclimation periods to stabilize baseline respiration.

Biopharma FAQs